vs
ANI PHARMACEUTICALS INC（ANIP）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
ROYAL GOLD INC的季度营收约是ANI PHARMACEUTICALS INC的1.5倍（$375.3M vs $247.1M），ROYAL GOLD INC净利率更高（24.9% vs 11.1%，领先13.8%），ROYAL GOLD INC同比增速更快（85.3% vs 29.6%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs 34.1%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
ANIP vs RGLD — 直观对比
营收规模更大
RGLD
是对方的1.5倍
$247.1M
营收增速更快
RGLD
高出55.7%
29.6%
净利率更高
RGLD
高出13.8%
11.1%
两年增速更快
RGLD
近两年复合增速
34.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $375.3M |
| 净利润 | $27.5M | $93.6M |
| 毛利率 | — | 64.6% |
| 营业利润率 | 14.1% | 56.2% |
| 净利率 | 11.1% | 24.9% |
| 营收同比 | 29.6% | 85.3% |
| 净利润同比 | 367.5% | -12.8% |
| 每股收益（稀释后） | $1.14 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRGLD
| Q4 25 | $247.1M | $375.3M | ||
| Q3 25 | $227.8M | $252.1M | ||
| Q2 25 | $211.4M | $209.6M | ||
| Q1 25 | $197.1M | $193.4M | ||
| Q4 24 | $190.6M | $202.6M | ||
| Q3 24 | $148.3M | $193.8M | ||
| Q2 24 | $138.0M | $174.1M | ||
| Q1 24 | $137.4M | $148.9M |
净利润ANIPRGLD
| Q4 25 | $27.5M | $93.6M | ||
| Q3 25 | $26.6M | $126.8M | ||
| Q2 25 | $8.5M | $132.3M | ||
| Q1 25 | $15.7M | $113.5M | ||
| Q4 24 | $-10.3M | $107.4M | ||
| Q3 24 | $-24.2M | $96.2M | ||
| Q2 24 | $-2.3M | $81.2M | ||
| Q1 24 | $18.2M | $47.2M |
毛利率ANIPRGLD
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 73.6% | ||
| Q2 25 | — | 72.6% | ||
| Q1 25 | — | 69.4% | ||
| Q4 24 | — | 70.3% | ||
| Q3 24 | — | 66.6% | ||
| Q2 24 | — | 64.7% | ||
| Q1 24 | — | 58.4% |
营业利润率ANIPRGLD
| Q4 25 | 14.1% | 56.2% | ||
| Q3 25 | 15.9% | 64.4% | ||
| Q2 25 | 6.6% | 67.7% | ||
| Q1 25 | 13.3% | 63.6% | ||
| Q4 24 | -2.3% | 65.9% | ||
| Q3 24 | -13.8% | 61.3% | ||
| Q2 24 | 3.7% | 58.6% | ||
| Q1 24 | 14.8% | 50.7% |
净利率ANIPRGLD
| Q4 25 | 11.1% | 24.9% | ||
| Q3 25 | 11.7% | 50.3% | ||
| Q2 25 | 4.0% | 63.1% | ||
| Q1 25 | 8.0% | 58.7% | ||
| Q4 24 | -5.4% | 53.0% | ||
| Q3 24 | -16.3% | 49.7% | ||
| Q2 24 | -1.7% | 46.6% | ||
| Q1 24 | 13.2% | 31.7% |
每股收益（稀释后）ANIPRGLD
| Q4 25 | $1.14 | $1.04 | ||
| Q3 25 | $1.13 | $1.92 | ||
| Q2 25 | $0.36 | $2.01 | ||
| Q1 25 | $0.69 | $1.72 | ||
| Q4 24 | $-0.45 | $1.63 | ||
| Q3 24 | $-1.27 | $1.46 | ||
| Q2 24 | $-0.14 | $1.23 | ||
| Q1 24 | $0.82 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $233.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $7.2B |
| 总资产 | $1.4B | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPRGLD
| Q4 25 | $285.6M | $233.7M | ||
| Q3 25 | $262.6M | $172.8M | ||
| Q2 25 | $217.8M | $248.2M | ||
| Q1 25 | $149.8M | $240.8M | ||
| Q4 24 | $144.9M | $195.5M | ||
| Q3 24 | $145.0M | $127.9M | ||
| Q2 24 | $240.1M | $74.2M | ||
| Q1 24 | $228.6M | $137.9M |
总债务ANIPRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M | ||
| Q1 24 | — | — |
股东权益ANIPRGLD
| Q4 25 | $540.7M | $7.2B | ||
| Q3 25 | $505.8M | $3.4B | ||
| Q2 25 | $436.8M | $3.3B | ||
| Q1 25 | $418.6M | $3.2B | ||
| Q4 24 | $403.7M | $3.1B | ||
| Q3 24 | $405.9M | $3.0B | ||
| Q2 24 | $455.8M | $3.0B | ||
| Q1 24 | $452.0M | $2.9B |
总资产ANIPRGLD
| Q4 25 | $1.4B | $9.5B | ||
| Q3 25 | $1.4B | $4.5B | ||
| Q2 25 | $1.3B | $3.6B | ||
| Q1 25 | $1.3B | $3.5B | ||
| Q4 24 | $1.3B | $3.4B | ||
| Q3 24 | $1.3B | $3.3B | ||
| Q2 24 | $920.8M | $3.3B | ||
| Q1 24 | $914.5M | $3.3B |
负债/权益比ANIPRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | 2.58× |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPRGLD
| Q4 25 | $30.4M | $241.7M | ||
| Q3 25 | $44.1M | $174.0M | ||
| Q2 25 | $75.8M | $152.8M | ||
| Q1 25 | $35.0M | $136.4M | ||
| Q4 24 | $15.9M | $141.1M | ||
| Q3 24 | $12.5M | $136.7M | ||
| Q2 24 | $17.4M | $113.5M | ||
| Q1 24 | $18.3M | $138.3M |
自由现金流ANIPRGLD
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
自由现金流率ANIPRGLD
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
资本支出强度ANIPRGLD
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
现金转化率ANIPRGLD
| Q4 25 | 1.10× | 2.58× | ||
| Q3 25 | 1.66× | 1.37× | ||
| Q2 25 | 8.87× | 1.15× | ||
| Q1 25 | 2.23× | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | 1.00× | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
